Movano health's proprietary cuffless blood pressure device once again achieves accuracy commensurate with the fda's requirements

Leveraging the company's system-on-a-chip (soc), the clinical study results are another significant step forward in commercializing a cuffless, radio frequency (rf)-enabled blood pressure device pleasanton, calif. , april 22, 2025 /prnewswire/ -- movano health (nasdaq: move), a pioneer in health technology, today announced positive results of its most recent 81-participant blood pressure clinical study.
MOVE Ratings Summary
MOVE Quant Ranking